News Daily News Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure Michael O'Riordan December 30, 2025
News Daily News Remission From Prediabetes Halves CV Risk: Registry Data Yael L. Maxwell December 19, 2025
News Daily News SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide Michael O'Riordan December 18, 2025
News Daily News Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION Todd Neale December 16, 2025
News Daily News Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER Michael O'Riordan December 12, 2025
News Conference News AHA 2025 Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia Michael O'Riordan November 14, 2025
News Conference News AHA 2025 Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids Michael O'Riordan November 10, 2025
News Conference News AHA 2025 Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia Caitlin E. Cox November 08, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Daily News Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients Caitlin E. Cox October 16, 2025
News Daily News High Aerobic Fitness Linked to Less Chronic Disease in Later Life Michael O'Riordan October 10, 2025
News Daily News Risk Factors Present in Nearly All Patients Who Develop CVD Michael O'Riordan October 02, 2025
News Opinion CV Team Dispatch September 2025 Dispatch for the CV Team L.A. McKeown September 30, 2025
News Daily News CVD Still the Leading Cause of Death and Disease Globally Michael O'Riordan September 24, 2025
News Daily News Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions L.A. McKeown September 22, 2025
News Daily News Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s Michael O'Riordan September 18, 2025
News Daily News Half of Patients Stop Semaglutide for Weight Loss by 1 Year Todd Neale September 18, 2025